Total neoadjuvant therapy with split-course hypofraction radiotherapy combined with CAPOX and envafolimab followed by local excision for locally advanced very low rectal cancer (TRACE-LE): An open-label, single-arm, multicenter, phase II trial

被引：0
|
作者：
Jiang, Weizhong
Chi, Pan
Tao, Kaixiong
Xu, Dongbo
Yang, Chunkang
Zheng, Rong
Xu, Benhua
Huang, Ying
Chen, Zhifen
Huang, Shenghui
Xu, Zongbin
机构：
[1] Fujian Med Univ, Dept Colorectal Surg, Union Hosp, Fuzhou, Fujian, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Med Coll, Wuhan, Peoples R China
[3] Fujian Med Univ, Longyan Affiliated Hosp, Longyan, Peoples R China
[4] Fujian Prov Canc Hosp, Fuzhou, Peoples R China
[5] Fujian Med Univ, Dept Radiat Oncol, Union Hosp, Fuzhou, Fujian, Peoples R China
[6] Fujian Med Univ, Dept Colorectal Surg, Union Hosp, Fuzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3647
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Effect of neoadjuvant chemotherapy and early chemotherapeutic low/intermediated-risk mid-low stage II/III rectal cancer: A prospective, open-label, single-arm, phase II trial.
    Deng, Xiangbing
    Bi, Liang
    Wu, Qingbin
    He, Du
    Gou, Hongfeng
    Wu, Bing
    Yu, Yongyang
    Meng, Wenjian
    Meng, Qiu
    Wang, Ziqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
    Bahadoer, Renu R.
    Dijkstra, Esmee A.
    van Etten, Boudewijn
    Marijnen, Corrie A. M.
    Putter, Hein
    Kranenbarg, Elma Meershoek-Klein
    Roodvoets, Annet G. H.
    Nagtegaal, Iris D.
    Beets-Tan, Regina G. H.
    Blomqvist, Lennart K.
    Fokstuen, Tone
    ten Tije, Albert J.
    Capdevila, Jaume
    Hendriks, Mathijs P.
    Edhemovic, Ibrahim
    Cervantes, Andres
    Nilsson, Per J.
    Glimelius, Bengt
    van de Velde, Cornelis J. H.
    Hospers, Geke A. P.
    LANCET ONCOLOGY, 2021, 22 (01): : 29 - 42
  • [43] Short-course radiation(SCRT) followed by 6 cycles of cadonilimab plus mFOLFOX6 as neoadjuvant therapy for patients with locally advanced rectal cancer (LARC): A multicenter, single arm, phase II trial (NeoCaCRT).
    He, Wan
    Huang, Jun
    Liao, Guixiang
    Li, Wenwen
    Shen, Jing
    Fu, Yuxiang
    Tang, Na
    He, Fang
    Zhao, Yandong
    Liu, Zhimin
    Shi, Lishuo
    Pei, Fengyun
    Yao, Qijun
    Zhong, Xiaoling
    Zhong, Keli
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : LBA210 - LBA210
  • [44] Efficacy and safety of sequential neoadjuvant chemotherapy and short-course radiation therapy followed by delayed surgery in locally advanced rectal cancer: a single-arm phase II clinical trial with subgroup analysis between the older and young patients
    Bananzadeh, Alimohammad
    Hafezi, Ali Akbar
    Nguyen, NamPhong
    Omidvari, Shapour
    Mosalaei, Ahmad
    Ahmadloo, Niloofar
    Ansari, Mansour
    Mohammadianpanah, Mohammad
    RADIATION ONCOLOGY JOURNAL, 2021, 39 (04): : 270 - 278
  • [45] Anlotinib combined with whole brain radiation therapy (WBRT) for advanced non-small cell lung cancer with multiple brain metastases: An open-label, single-arm phase II trial
    Zhu, X.
    Tao, H.
    Kong, C.
    Song, X.
    Zhang, N.
    Chen, C.
    Jiang, N.
    Zhao, L.
    Yan, P.
    He, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S881 - S881
  • [46] Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTINEOGA) protocol
    Wu, Liucheng
    Yan, Haiqing
    Qin, Yuzhou
    Huang, Mingwei
    Wang, Tingan
    Jin, Qinwen
    Wei, Weiyuan
    BMJ OPEN, 2024, 14 (02):
  • [47] Phase II open-label single-arm study of pre-operative panitumumab and external pelvic radiotherapy (RTE) in locally advanced rectal cancer (LARC) patients (pts) (RaP/STAR-03 Study)
    Pinto, C.
    Di Bisceglie, M.
    Di Fabio, F.
    Bochicchio, A. M.
    Latiano, T.
    Cordio, S.
    Rosati, G.
    Aschele, C.
    Marino, A.
    Bergamo, F.
    Bustreo, S.
    Frassineti, L.
    Ciardiello, F.
    Giaquinta, S.
    Baldari, D.
    Boni, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)
    Shang, Xiaobin
    Zhao, Gang
    Liang, Fei
    Zhang, Chen
    Zhang, Weihong
    Liu, Liang
    Li, Runmei
    Duan, Xiaofeng
    Ma, Zhao
    Yue, Jie
    Chen, Chuangui
    Meng, Bin
    Ren, Xiubao
    Jiang, Hongjing
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (04)
  • [49] Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial)
    Yang, Zhengyang
    Zhang, Xiao
    Zhang, Jie
    Gao, Jiale
    Bai, Zhigang
    Deng, Wei
    Chen, Guangyong
    An, Yongbo
    Liu, Yishan
    Wei, Qi
    Han, Jiagang
    Li, Ang
    Liu, Gang
    Sun, Yi
    Kong, Dalu
    Yao, Hongwei
    Zhang, Zhongtao
    BMC CANCER, 2022, 22 (01)
  • [50] Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial)
    Zhengyang Yang
    Xiao Zhang
    Jie Zhang
    Jiale Gao
    Zhigang Bai
    Wei Deng
    Guangyong Chen
    Yongbo An
    Yishan Liu
    Qi Wei
    Jiagang Han
    Ang Li
    Gang Liu
    Yi Sun
    Dalu Kong
    Hongwei Yao
    Zhongtao Zhang
    BMC Cancer, 22
12345